New Computational Tools for Modeling Chronic Myelogenous Leukemia
暂无分享,去创建一个
Silviu-Iulian Niculescu | Matthew M. Peet | Doron Levy | Peter S. Kim | S. Niculescu | D. Levy | P. Kim | M. Peet
[1] Silviu-Iulian Niculescu,et al. ON STABILITY OF A COMBINED GLEEVEC AND IMMUNE MODEL IN CHRONIC LEUKEMIA: EXPLOITING DELAY SYSTEM STRUCTURE , 2007 .
[2] J. Hale,et al. Stability of Motion. , 1964 .
[3] Laurent Pujo-Menjouet,et al. Contribution to the study of periodic chronic myelogenous leukemia. , 2004, Comptes rendus biologies.
[4] Antonis Papachristodoulou,et al. Analysis of Polynomial Systems With Time Delays via the Sum of Squares Decomposition , 2009, IEEE Transactions on Automatic Control.
[5] Martin A. Nowak,et al. Dynamics of chronic myeloid leukaemia , 2005, Nature.
[6] J. Altman,et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. , 1998, Immunity.
[7] Adam Bagg,et al. Chronic myeloid leukemia: a minimalistic view of post-therapeutic monitoring. , 2002, The Journal of molecular diagnostics : JMD.
[8] Helen Moore,et al. A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction. , 2004, Journal of theoretical biology.
[9] Mark M. Davis,et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia , 2000, Nature Medicine.
[10] Jos F. Sturm,et al. A Matlab toolbox for optimization over symmetric cones , 1999 .
[11] Gerhard Ehninger,et al. Kinetics of stem cell engraftment and clearance of leukaemia cells after allogeneic stem cell transplantation with reduced intensity conditioning in chronic myeloid leukaemia , 2002, European journal of haematology.
[12] Laurent Pujo-Menjouet,et al. A mathematical model describing cellular division with a proliferating phase duration depending on the maturity of cells. , 2003 .
[13] G. Weisbuch,et al. Immunology for physicists , 1997 .
[14] Richard J. Jones,et al. Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant , 2004, Current opinion in oncology.
[15] R. Larson,et al. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL1 , 2003, Leukemia.
[16] P. Paschka,et al. Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission , 2003, Leukemia.
[17] van der Arjan Schaft,et al. Proceedings of the 47th IEEE Conference on Decision and Control, CDC 2008, December 9-11, 2008, Cancún, Mexico , 2008, CDC.
[18] Susan O'Brien,et al. Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate , 2005, Clinical Cancer Research.
[19] Brent Neiman,et al. A Mathematical Model of Chronic Myelogenous Leukemia , 2000 .
[20] Matthew M. Peet,et al. Exponentially Stable Nonlinear Systems Have Polynomial Lyapunov Functions on Bounded Regions , 2007, IEEE Transactions on Automatic Control.
[21] Robert H. Collins,et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Els Goulmy,et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[24] Stephen P. Schoenberger,et al. Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation , 2001, Nature Immunology.
[25] SFT Thijsen,et al. Chronic myeloid leukemia from basics to bedside , 1999, Leukemia.
[26] Dominik Wodarz,et al. Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[27] Alan S. Perelson,et al. Stochastic stage-structured modeling of the adaptive immune system , 2003, Computational Systems Bioinformatics. CSB2003. Proceedings of the 2003 IEEE Bioinformatics Conference. CSB2003.
[28] Michael C Mackey,et al. A mathematical model of hematopoiesis: II. Cyclical neutropenia. , 2005, Journal of theoretical biology.
[29] Patrick W Nelson,et al. Mathematical analysis of delay differential equation models of HIV-1 infection. , 2002, Mathematical biosciences.
[30] R. Larson,et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. , 2002, Blood.
[31] J. B. Chatterjea,et al. Chronic myelogenous leukaemia , 1973, Indian journal of pediatrics.
[32] Jonas Mattsson,et al. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. , 2003, Blood.
[33] Michael C Mackey,et al. A mathematical model of hematopoiesis--I. Periodic chronic myelogenous leukemia. , 2005, Journal of theoretical biology.
[34] Ami Radunskaya,et al. A delay differential equation model for tumor growth , 2003, Journal of mathematical biology.
[35] P. Klenerman,et al. Low level viral persistence after infection with LCMV: a quantitative insight through numerical bifurcation analysis. , 2001, Mathematical biosciences.
[36] Eric G. Pamer,et al. Early Programming of T Cell Populations Responding to Bacterial Infection1 , 2000, The Journal of Immunology.
[37] Susan M. Kaech,et al. Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells , 2001, Nature Immunology.
[38] D. Neuberg,et al. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. , 1998, Blood.
[39] Antonis Papachristodoulou,et al. Positive Forms and Stability of Linear Time-Delay Systems , 2006, Proceedings of the 45th IEEE Conference on Decision and Control.
[40] Carl T. Bergstrom,et al. Models of CD8+ responses: 1. What is the antigen-independent proliferation program. , 2003, Journal of theoretical biology.
[41] Yinyu Ye,et al. DSDP5: Software for Semidefinite Programming , 2005 .
[42] Frédéric Mazenc,et al. Stability of a Gleevec and immune model with delays , 2008, 2008 47th IEEE Conference on Decision and Control.
[43] Holden T Maecker,et al. Development and dynamics of robust T-cell responses to CML under imatinib treatment. , 2008, Blood.
[44] G. Stengle. A nullstellensatz and a positivstellensatz in semialgebraic geometry , 1974 .
[45] T. Klingebiel,et al. GVHD: overview on pathophysiology, incidence, clinical and biological features. , 1998, Bone marrow transplantation.
[46] A Ferrant,et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.
[47] Ingo Roeder,et al. Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications , 2006, Nature Medicine.
[48] C. Sawyers. Chronic myeloid leukemia. , 1999, The New England journal of medicine.
[49] Ju Hyun Park,et al. Stability Analysis of Linear Time-delay Systems , 1996 .